Vigil Neuroscience (NASDAQ:VIGL) Rating Lowered to Hold at Citizens Jmp

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) was downgraded by equities researchers at Citizens Jmp from a "strong-buy" rating to a "hold" rating in a report issued on Thursday,Zacks.com reports.

VIGL has been the subject of several other reports. Jefferies Financial Group cut shares of Vigil Neuroscience to a "hold" rating in a report on Thursday. Citigroup lowered Vigil Neuroscience to a "market perform" rating in a report on Thursday. JMP Securities reaffirmed a "market perform" rating on shares of Vigil Neuroscience in a report on Thursday. HC Wainwright lowered their target price on Vigil Neuroscience from $17.00 to $14.00 and set a "buy" rating on the stock in a report on Friday, March 14th. Finally, Wedbush lowered Vigil Neuroscience from a "strong-buy" rating to a "hold" rating and lowered their target price for the stock from $13.00 to $8.00 in a report on Thursday. Seven research analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat, Vigil Neuroscience presently has an average rating of "Hold" and an average price target of $13.00.

Vigil Neuroscience Stock Performance

Shares of VIGL stock opened at $7.88 on Thursday. Vigil Neuroscience has a 1 year low of $1.31 and a 1 year high of $7.95. The stock has a fifty day moving average of $2.07 and a two-hundred day moving average of $2.27. The firm has a market capitalization of $367.78 million, a PE ratio of -3.83 and a beta of 1.90.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.53) by $0.04. Equities research analysts predict that Vigil Neuroscience will post -2.07 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vigil Neuroscience

A number of hedge funds and other institutional investors have recently modified their holdings of VIGL. abrdn plc raised its holdings in Vigil Neuroscience by 124.9% during the 4th quarter. abrdn plc now owns 528,472 shares of the company's stock worth $898,000 after buying an additional 293,461 shares during the period. Cubist Systematic Strategies LLC increased its position in shares of Vigil Neuroscience by 53.0% in the fourth quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock worth $41,000 after acquiring an additional 8,358 shares in the last quarter. Barclays PLC raised its holdings in shares of Vigil Neuroscience by 43.6% during the fourth quarter. Barclays PLC now owns 64,049 shares of the company's stock valued at $109,000 after acquiring an additional 19,436 shares during the period. Blair William & Co. IL purchased a new position in Vigil Neuroscience during the 4th quarter worth approximately $551,000. Finally, 683 Capital Management LLC grew its position in Vigil Neuroscience by 14.8% during the 4th quarter. 683 Capital Management LLC now owns 1,400,000 shares of the company's stock worth $2,380,000 after purchasing an additional 180,420 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company's stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.